Serum Pentraxin 3 A Marker in Diagnosing Acute Coronary Syndrome

Abstract

Background: Acute coronary syndrome (ACS) denotes the acute phase of ischemic coronary artery disease with or without myocardial necrosis. It is the initial working diagnosis later refined by electrocardiography and biomarkers. Diagnostic sensitivity and specificity for ACS, especially at the earliest stage remains insufficient. Pentraxin 3 (PTX3) is the inflammatory protein and has the potential to be a biomarker in the diagnosis of ACS, as it is elevated in the early hours (6-8 h) of ACS. The aim of the study is to estimate serum PTX3 level in patients with ACS and to correlate with serum creatine kinase-MB (CK-MB) and lipid parameters. Materials and Methods: A study group includes 50 patients who were admitted in Intensive Cardiac Care Unit with ACS and 50 participants of age- and sex-matched healthy individuals were taken as control. Assay of serum PTX3 was done by ELISA method and CK-MB by kinetic immune inhibition method. Serum lipid profile was measured by colorimetric method. Results: Serum PTX3 levels (mean: 5.607 ± 2.82 ng/ml) were elevated in the ACS compared to normal healthy persons (mean: 1.38 ± 0.52 ng/ml) and are statistically significant (P < 0.05), and there is no correlation between serum PTX3 levels, CK-MB, and lipid profile. Conclusion: The elevated concentration of serum PTX3, in early hours (6-8 h) of ACS, is a novel biomarker for diagnosing patients.

Keywords

• acute coronary syndrome
• creatine kinase-mb
• lipid parameters
• pentraxin 3